A healthcare company in China headquartered in Shanghai, China focuses on patent licensing, technology acquisition, joint development, etc. The firm seeks new technologies and projects across Greater China, the US, and some European countries.

In the life sciences, the firm is currently looking for innovative therapeutics companies. The firm will focus on assets in five indication areas: oncology, CNS, cardiovascular, metabolic disease and nutritional, and infectious diseases. For the type of modality, the firm is open to companies developing small molecule, biologics, gene therapy and cell therapy. The firm is most interested in products in clinical phase II and phase III stage, but will consider earlier stage companies that show promising technologies.

The firm is interested in privately held life science companies with experienced management teams and innovative technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm that has been actively investing for over 20 years with multiple offices in Europe has over €1 billion in total assets under management and recently closed its first dedicated Health Tech Fund, after successfully investing in the sector from mixed vehicles for more than 20 years. The firm typically invests €1-5 million in early-stage opportunities or up to €10 million in growth-stage opportunities. The firm is currently focused on companies based in Europe.

Within the life science sector, the firm is currently focused on medical technology, diagnostics, life science tools and platforms, and digital health across Europe. The firm is open to opportunities in any indication area and at any phase of development.

The firm is open to investing in companies at early stages with a proof-of-concept, clinically relevant data and/or strong IP positions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A transatlantic investor firm headquartered in Europe with additional offices in USA has managed more than $800 million in total assets across six specialized funds. 2 of their funds focus on healthcare service providers based in the Benelux and Germany, and 4 of their funds focus on investing in companies developing therapeutics, medical devices, diagnostics and digital health. The most recent fund closed at $280 million. The firm prefers to invest in clinical stage therapeutics companies and commercial stage diagnostics/medical technology companies. The investment size ranges from $5 million up to $30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large healthcare group that operates 80+ hospitals across Asia, the Middle East and Turkey has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.

The firm only invests in the digital health space. The firm is interested in many areas of digital health that are applicable to hospitals, including predictive analytics, genomic data, and AI. The firm does not invest in biopharma or medtech.

The firm will invest globally, and is focused on startups that are interested in expanding into Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital firm founded in 1995 has offices in the Silicon Valley area and China. The firm recently closed a $750 million fund as well as a smaller $150 million fund. The firm invests exclusively in the life science sector and invests primarily in the USA and China, but will also invest in other regions such as Europe and Canada. Within China, the firm makes growth investments in companies that have existing revenues; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $10-30m, though larger investments are of interest as well; the firm’s smaller fund makes investments of typically $2-5 million, generally in financing rounds of $10 million or less. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, and blood diseases are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. The smaller fund focuses on early stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams, and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, The firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large Indian conglomerate headquartered has many subsidiary companies, several of which are involved within the life science space. Within the hospital subsidiary, the firm is particularly interested in technologies that can help reduce costs, increase access for patient populations, process data, and keep records. The firm also runs their own incubator. The firm is currently interested in Seed and Series A opportunities where they can put in $1-2 million USD. The firm also currently prefers co-investing over leading. The firm is interested in opportunities globally, but prefers if they have an interest in working in India.

The firm is particularly interested in the digital health space, specifically telemedicine and AI-based data processing. The firm is interested in these technologies as they believe that they can leverage digital health solutions in order to reduce costs within their hospital systems as well as increase the access to patients located in remote areas. The firm is also interested in Ai-based record keeping and analytic technologies as currently, medical records in India are minimal. The firm is also interested in technology related to disaster management and response. The firm is also interested in technologies that can be used to establish clinics in pharmacies as they’ve seen a trend for patients to prefer clinic visits over hospital visit in India. The firm is also particularly interested in natural remedies, specifically the use of organic and natural ingredients in Ayurveda (traditional Indian medicine). The firm also has a slight interest in genomics, but they would only be interested if a strong lead investor with genomics experience is already in place. The firm prefers investing in companies that already have proof of concept.

The firm prefers a strong management team that is dedicated and focused on seeing the project through to the end. The firm also prefers to invest alongside strong lead investors with significant experience in the field. The firm prefers to take a board seat when investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in China with offices in Beijing, Shanghai, Suzhou, Shenzhen, and Hong Kong manages about USD 1 billion in committed capital with five USD funds and five RMB funds. The firm typically invests in series A and B rounds; however the firm prefers seed or angel rounds when it comes to overseas opportunities. The firm can invest anywhere from a few hundred thousand dollars up to ten million or more over a 10 year horizon. At present, the firm is looking for new investment opportunities in Greater China, while it also considers US- or EU-based companies with excellent technology that are Chinese-led or have a China angle.

The firm seeks to invest in a broad array of technologies including therapeutics, medical devices, IVD, e-Health and etc. Within therapeutics, the firm is interested in innovative drugs and novel biotechnology based therapies. Within medical devices, the firm is interested in a great range of devices and disposables that address large unmet medical need in China. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in immuno-oncology drugs, CNS drugs, gene therapy and gene editing, digital health and AI-backed diagnostics, radiology imaging, clinical cell and molecular genetics testing, POC devices, diagnostics and genomics, and so on.

The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.